JP2016530291A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016530291A5 JP2016530291A5 JP2016539645A JP2016539645A JP2016530291A5 JP 2016530291 A5 JP2016530291 A5 JP 2016530291A5 JP 2016539645 A JP2016539645 A JP 2016539645A JP 2016539645 A JP2016539645 A JP 2016539645A JP 2016530291 A5 JP2016530291 A5 JP 2016530291A5
- Authority
- JP
- Japan
- Prior art keywords
- metadoxine
- composition
- sustained release
- disorder
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- RYKKQQUKJJGFMN-HVDRVSQOSA-N 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol;(2s)-5-oxopyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCC(=O)N1.CC1=NC=C(CO)C(CO)=C1O RYKKQQUKJJGFMN-HVDRVSQOSA-N 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 9
- 239000012730 sustained-release form Substances 0.000 claims 6
- 238000013268 sustained release Methods 0.000 claims 4
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 206010000117 Abnormal behaviour Diseases 0.000 claims 1
- 208000001914 Fragile X syndrome Diseases 0.000 claims 1
- 208000020358 Learning disease Diseases 0.000 claims 1
- 208000029560 autism spectrum disease Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 230000011273 social behavior Effects 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361875384P | 2013-09-09 | 2013-09-09 | |
| US61/875,384 | 2013-09-09 | ||
| US14/038,258 US20150073023A1 (en) | 2013-09-09 | 2013-09-26 | Method Of Treating Fragile X Syndrome And Related Disorders |
| US14/038,258 | 2013-09-26 | ||
| US201461991351P | 2014-05-09 | 2014-05-09 | |
| US61/991,351 | 2014-05-09 | ||
| PCT/IB2014/002398 WO2015033224A2 (en) | 2013-09-09 | 2014-09-09 | Methods of treating fragile x syndrome and related disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016530291A JP2016530291A (ja) | 2016-09-29 |
| JP2016530291A5 true JP2016530291A5 (enExample) | 2017-10-19 |
Family
ID=52629036
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016539645A Pending JP2016530291A (ja) | 2013-09-09 | 2014-09-09 | 脆弱ｘ症候群および関連障害の処置方法 |
| JP2016540930A Pending JP2016530536A (ja) | 2013-09-09 | 2014-09-09 | 療法に対する奏効性の決定方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016540930A Pending JP2016530536A (ja) | 2013-09-09 | 2014-09-09 | 療法に対する奏効性の決定方法 |
Country Status (12)
| Country | Link |
|---|---|
| EP (2) | EP3043792A2 (enExample) |
| JP (2) | JP2016530291A (enExample) |
| KR (2) | KR20160078956A (enExample) |
| CN (2) | CN105517546A (enExample) |
| AU (2) | AU2014316779A1 (enExample) |
| CA (2) | CA2923421A1 (enExample) |
| EA (2) | EA201690559A1 (enExample) |
| IL (2) | IL244343A0 (enExample) |
| MX (2) | MX2016003002A (enExample) |
| SG (2) | SG11201601830PA (enExample) |
| TW (2) | TW201606304A (enExample) |
| WO (2) | WO2015033224A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102226202B1 (ko) * | 2013-07-31 | 2021-03-12 | 유디씨 아일랜드 리미티드 | 발광 디아자벤즈이미다졸 카르벤 금속 착물 |
| US20150073023A1 (en) | 2013-09-09 | 2015-03-12 | Alcobra Ltd. | Method Of Treating Fragile X Syndrome And Related Disorders |
| CN108538365A (zh) * | 2017-03-24 | 2018-09-14 | 华东师范大学 | 一种基于数据分析技术的自闭症社交能力评估系统 |
| US12582664B2 (en) | 2017-09-28 | 2026-03-24 | Harmony Biosciences Management, Inc. | Treatment of fragile x syndrome with cannabidiol |
| US10864182B2 (en) * | 2018-04-13 | 2020-12-15 | Healx Limited | Treatment of fragile X syndrome |
| KR20190121569A (ko) * | 2018-04-18 | 2019-10-28 | 건국대학교 글로컬산학협력단 | 아그마틴 및 이의 약학적으로 허용 가능한 염을 포함하는 취약 x 증후군 예방 또는 치료용 약학조성물 |
| EP3813816B1 (en) * | 2018-06-07 | 2023-06-07 | Ovid Therapeutics Inc. | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid in the treatment of fragile x syndrome or fragile x-associated tremor/ataxia syndrome |
| US20230024384A1 (en) * | 2020-01-08 | 2023-01-26 | Neuroventi | Composition comprising lisuride compound for treating fragile x syndrome or related developmental disorders |
| WO2021158059A1 (ko) * | 2020-02-07 | 2021-08-12 | 건국대학교 글로컬산학협력단 | 릴메니딘 화합물을 유효성분으로 포함하는 취약 x 증후군 또는 관련 발달 장애 치료용 조성물 |
| IL299399A (en) * | 2020-06-29 | 2023-02-01 | Zynerba Pharmaceuticals Inc | Treatment of fragile X syndrome with cannabidiol |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1131856B (it) | 1980-06-30 | 1986-06-25 | Baldacci Lab Spa | Composizione farmaceutica per il trattamento di intossicazioni alcooliche |
| AU2002236527A1 (en) * | 2000-11-30 | 2002-06-11 | The Health Research Institute | Nutrient supplements and methods for treating autism and for preventing the onset of autism |
| IL187159A0 (en) | 2007-07-03 | 2009-02-11 | Gur Megiddo | Use of metadoxine in relief of alcohol intoxication |
| EA023758B1 (ru) * | 2009-06-25 | 2016-07-29 | Алкобра Лтд. | Применение метадоксина для лечения синдрома дефицита внимания/гиперактивности (adhd/add) |
-
2014
- 2014-09-05 TW TW103130859A patent/TW201606304A/zh unknown
- 2014-09-05 TW TW103130856A patent/TW201605443A/zh unknown
- 2014-09-09 JP JP2016539645A patent/JP2016530291A/ja active Pending
- 2014-09-09 CA CA2923421A patent/CA2923421A1/en not_active Abandoned
- 2014-09-09 CN CN201480049671.5A patent/CN105517546A/zh active Pending
- 2014-09-09 EA EA201690559A patent/EA201690559A1/ru unknown
- 2014-09-09 KR KR1020167009040A patent/KR20160078956A/ko not_active Withdrawn
- 2014-09-09 SG SG11201601830PA patent/SG11201601830PA/en unknown
- 2014-09-09 MX MX2016003002A patent/MX2016003002A/es unknown
- 2014-09-09 SG SG11201601605YA patent/SG11201601605YA/en unknown
- 2014-09-09 CN CN201480060722.4A patent/CN105917225A/zh active Pending
- 2014-09-09 JP JP2016540930A patent/JP2016530536A/ja active Pending
- 2014-09-09 KR KR1020167009042A patent/KR20160086818A/ko not_active Withdrawn
- 2014-09-09 AU AU2014316779A patent/AU2014316779A1/en not_active Abandoned
- 2014-09-09 CA CA2922901A patent/CA2922901A1/en not_active Abandoned
- 2014-09-09 AU AU2014315026A patent/AU2014315026A1/en not_active Abandoned
- 2014-09-09 WO PCT/IB2014/002398 patent/WO2015033224A2/en not_active Ceased
- 2014-09-09 EA EA201690557A patent/EA201690557A1/ru unknown
- 2014-09-09 WO PCT/US2014/054816 patent/WO2015035402A1/en not_active Ceased
- 2014-09-09 EP EP14830858.8A patent/EP3043792A2/en not_active Withdrawn
- 2014-09-09 EP EP14776939.2A patent/EP3044589A1/en not_active Withdrawn
- 2014-09-09 MX MX2016003006A patent/MX2016003006A/es unknown
-
2016
- 2016-02-29 IL IL244343A patent/IL244343A0/en unknown
- 2016-03-06 IL IL244453A patent/IL244453A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210819T1 (hr) | Fenfluramin za uporabu u liječenju dravet sindroma | |
| JP2012193216A5 (enExample) | ||
| JP2018193377A5 (enExample) | ||
| EA201690107A1 (ru) | Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе | |
| MY181159A (en) | Sublingual and buccal film compositions | |
| JP2015057451A5 (enExample) | ||
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| JP2014111603A5 (enExample) | ||
| JP2015515475A5 (enExample) | ||
| JP2010285439A5 (enExample) | ||
| JP2015517488A5 (enExample) | ||
| BR112015018168A2 (pt) | inibidores de rock suaves | |
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| JP2015525757A5 (enExample) | ||
| JP2013231087A5 (enExample) | ||
| MX2013003635A (es) | Compuestos de n-heteroarilo. | |
| CL2016002132A1 (es) | Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo. | |
| ECSP12011703A (es) | Composiciones farmacéuticas para el tratamiento del cáncer y otras enfermedades o trastornos | |
| JP2013541583A5 (enExample) | ||
| PH12012502083A1 (en) | Manufacturing of active-free granules and tablets comprising the same | |
| AR091351A1 (es) | Formulaciones de bromocriptina, metodo para mejorar el control glucemico y metodo para la fabricacion | |
| BR112014014795A2 (pt) | sistema de pélete de multiunidade de liberação imediata | |
| BR112014009580A2 (pt) | composição farmacêutica de omeprazol | |
| JP2014507475A5 (enExample) | ||
| PH12015501377A1 (en) | Solid unit with high fexofenadine content and process for the preparation thereof |